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F ebruary celebrates Black History Month to honor the individuals who have made contributions and efforts to advance rights and representation of disenfranchised communities of color.  
It also is a time for us to acknowledge and become more aware 
of disparities in healthcare as evidenced by poorer health outcomes in 
communities of color across a variety of disease states, including cancer. 
Socioeconomic factors contribute to some of these disparities. Financial 
toxicity of the cost of novel health interventions alone is challenging to 
some patients.  The ability to take time off from work or to have caregiver 
support during that time also is influenced by the financial stability of 
patients.  Access to care is on its own a fundamental contributor to this 
disparity. 
It is known and has been evaluated that clinical trial enrollment historically 
has lacked and continues to lack diversity as evident by an 
overrepresentation of white male participants. Clinical trials themselves 
also are commonly limited to open at institutions with robust research 
infrastructure which may not be available in marginalized communities;  
access to clinical trials is a barrier on its own for patients. In a recent 
analysis of pivotal trials in oncology, the proportion of racial/ethnic 
representation compared to the actual US population was incongruent: 
The COVID19 pandemic has disrupted our daily lives and how we conduct 
clinical practice; also it is forcing us to develop efficiencies and identify 
ways for us to optimize the conduct of clinical trials, such as harnessing 
telehealth tools and conducting Sponsor visits remotely.  We’ve also 
begun to utilize technology in ways that may improve access to trials for 
investigators but also patients. 
Partly through the development of these efficiencies there is a potential 
future that may influence our contemporary clinical research practices to 
be able to increase access to care and enable more patients to be able to 
tolerate the rigor of volunteering to participate in a clinical trial. 
References: Loree JM, et al.  Disparity of Race Reporting and Representation in Clinical Trials 
Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.; Nazha B, et 
al. Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of 
Immunotherapy. American Society of Clinical Oncology Educational Book 39 (May 17, 2019) 3-10. 
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Spotlight on Boca Raton Regional Hospital's Research Programs 
LYNN HEART AND VASCULAR INSTITUTE 
C 
ardiovascular disease continues to be the leading cause of death in the United 
States, but hope is on the horizon. Researchers are developing novel surgical and 
medical therapies that hold the promise of saving lives and improving patients’ 
quality of life at the time of surgery and for the months and years beyond. As a leader in 
cardiovascular healthcare, the Lynn Heart and Vascular Institute scientists are exploring 
a variety of methods — such as advanced medical devices and minimally invasive 
techniques — that could revolutionize cardiovascular surgery by bringing new and 
innovative therapies to our patients. 
Our cardiovascular research initiatives are focused in a number of interdisciplinary areas.  
These areas include cardiothoracic and vascular surgery, electrophysiology, and general 
cardiology. Our researchers, many of whom are also part of our clinical staff, are 
engaged in number of FDA-regulated clinical trials in collaboration with other academic 
institutions and select industry partners. Several of the studies are physician-initiated and 
are only available at Boca Raton 
Regional Hospital.   
The cardiovascular research team 
includes cardiothoracic and 
vascular surgeons, cardiologists, 
electrophysiologists, a senior 
research nurse, a research nurse, 
and a study coordinator, all part of 
the clinical team that run the 
clinical trials. They are supported 
by the Research Administration 
Office at Boca Raton Regional 
Hospital in contract and budget 
negotiations as well as regulatory 
submissions. The program has 
enrolled over 600 patients  and 
currently manages close to 100 
patients in clinical trials. 
—Stephanie A. Boodram, 
Research Data Analyst and  
Ileana M. Vargas, Regulatory 
Coordinator, Office of Research 
Administration & Lynn Cancer 
Institute Dr. Alexander Kulik and Dr. Anthony Lee review a case on the 
computer.  Dr. Kulik recently published the effects of lipid 
levels and statins on vein graft patency after CABG, findings 
from the ACTIVE Trial he led—article linked on page 6. 
Photo from brrh.com 
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T he Miami Cardiac and Vascular Institute (MCVI) Research group is now making available a new application or “app” for your phone that allows you to engage with 
all the open research trials at MCVI.  This app increases awareness and provides details 
about MCVI’s open investigational studies, with the bonus of supporting community 
practitioners when they want to offer the most advanced treatments and technologies to 
cardiovascular patients in our area.  
The app is called “High Enroll,” and it is a tool that 
solves common recruitment challenges, provides 
real time study-specific information, and is available 
for free in the Apple and Google Play app stores.  
High Enroll allows users to see all open research 
trials at MCVI, matches patient conditions to 
available research trials, empowers users with the 
ability to search for inclusion and exclusion criteria 
by specific diagnosis, and gives the contact 
information of the research personnel who can 
assist with each research study. This app solves 
common issues such as providers not having study 
information readily available, being unaware of  
studies that are open for enrollment, and/or not 
knowing how to contact the study coordinator or the 
investigator. It also provides an easy way to share 
studies with colleagues inside and outside Baptist 
Health South Florida (BHSF), facilitating access to 
research, and enhancing external collaborations.   
High Enroll was designed by research professionals 
and is tailored to provide real world solutions for 
MCVI. Since we went live with the app in December, 
we have suggested numerous enhancements to the 
software in response to our needs and the feedback 
from our physicians and research staff. MCVI has 
secured unlimited use of the app at BHSF and all its 
affiliates, referring practitioners, partners and 
institutions. MCVI can help other Centers of 
Excellence within BHSF to add their studies to the 
app to show a more complete portfolio of research at 
BHSF. 
If you are interested in learning more, please scan the QR code to the 
left, or you can contact Dr. Raul Herrera at raulh@baptisthealth.net or 
Aileen Rodriguez at aileenro@baptisthealth.net. 
—Aileen Rodriguez,  Project Manager, MCVI 
HIGH ENROLL APP 
 
Using Technology to Increase Enrollment on Clinical Trials 
Screenshot from High Enroll app 
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T 
he outbreak of the COVID-19 
pandemic has brought about a 
plethora of changes to the many 
facets of healthcare and clinical research 
studies worldwide. With the Centers for 
Disease Control and Prevention’s social 
distancing guidelines, and the increased risk 
of immunocompromised patients being 
exposed to the SARS-CoV-2 virus from in-
person medical visits, there has been an 
increase in the use of telehealth medicine 
among oncology practices and oncology 
clinical trials to prevent the spread of 
COVID-19.  
Cancer patients are 3.5x more likely to have 
an ICU admission, be on mechanical 
ventilation, and to die from COVID-19 than 
non-cancer patients.
1
 However, many 
cancer patients enrolled in clinical trials 
have expressed a strong desire to continue 
trial participation despite the increased risk 
of COVID-19 infection.
2
 Those among 
multidisciplinary teams also feel that the 
benefits outweigh the risks for this group, 
given the importance of clinical trials. 
Telehealth medicine, which utilizes video 
and audio consultations, online patient 
portals, patient wellness apps, and remote 
monitoring, offers a safer way to practice 
healthcare compared to in-person visits by 
limiting exposure to at-risk patients.
1
 In the 
setting of clinical trials, telehealth medicine 
presents an opportunity to reshape 
investigational drug studies by implementing 
siteless clinical trials (open access online 
databases) along with objective, sensitive, 
high frequency assessments gathered 
outside of research sites (such as local 
laboratories).
2,3
 However, a strict regulatory 
framework creates a grey area for telehealth 
medicine in clinical trials. 
The FDA, among many organizations, has 
recognized the significant impact that 
COVID-19 has had on the conduct of 
clinical trials; site closures, quarantines, 
supply of investigational drugs, travel 
limitations and infection among trial 
participants and research personnel have 
created many challenges in meeting 
protocol procedures, good clinical practice, 
and minimizing risks to trial integrity.
4
 
Although less effective than in-person 
patient visits, telehealth medicine has been 
implemented to combat the challenges of 
study visit schedules, missed visits, and 
patient monitoring. Protocol procedures can 
adapt, and the need for in-person 
participation is dependent upon the trial in 
question with non-binding recommendations 
set forth by the FDA to improve clinical trial 
efficacy in the COVID-19 era.
4
  
In summary, the COVID-19 pandemic has 
caused many roadblocks in the progress of 
oncology clinical trials. Telehealth medicine 
has proved very useful for general clinical 
practice, and its use in the clinical trial 
setting will continue to grow and adapt, 
ultimately increasing the efficiency of clinical 
trials throughout the Covid-19 pandemic. 
—Luis Molina, Pharmacy Student Volunteer 
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1Kircher, Sheetal M et al. “Telemedicine in Oncology and 
Reimbursement Policy During COVID-19 and Beyond.” JNCCN, 
1-7. doi:10.6004/jnccn.2020.7639 
2Araujo DV, Watson GA, Siu LL. The Day After COVID-19—Time 
to Rethink Oncology Clinical Research. JAMA Oncol. 2021;7
(1):23–24. doi:10.1001/jamaoncol.2020.4240 
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How the Pandemic Affected Telehealth with Regard to Clinical Trial Efficiency 
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What are they and what do they mean? 
CITATION INDICES 
D issemination is an important part of the scientific process that allows others to replicate studies, interpret 
data, and build upon the results to further 
scientific progress.  However, how can one 
determine the reach or influence of their 
research?  Citation indices attempt to do just 
that.  Three indices to be discussed here are 
the i10-index, H-index, and G-index.  
These indices are derived from the total 
number of times a given published scholarly 
article or group of articles has been cited. 
The easiest to understand is the i10-index.  
Simply, it is the number of scholarly articles 
one has published that have been cited by at 
least 10 other articles.  The advantage is that 
the index is simple to understand; the 
disadvantage is that only Google Scholar 
provides and uses this index.   
A more complicated index is the H-index, 
named after physicist Jorge E. Hirsch, 
measures the scientific quantity and impact 
of an author.  In essence, how many N 
articles have been cited ≥ N times?  For 
example, if one has 20 articles, and 17 of the 
most highly cited articles each were cited 17 
or more times, then the H-index is 17.  The 
advantage of this index is that it is commonly 
used and allows for direct comparison of 
researchers within a field.  A disadvantage is 
that it does not allow one to compare 
researchers in different fields directly 
because those fields may have different 
ranges of H-indices.  Also, it is not accurate 
for people just starting their career who likely 
have only a few publications so far.   
The most complex of the three is the G-
index, proposed by Leo Egghe to account 
for more highly cited publications.  Using the 
example above, if one has 20 scholarly 
articles, and 17 of the most highly cited 
articles together were cited at least 17
2
=289 
times, then one’s G-index is 17.  In this 
example, one article could have had 200 
citations, and the other 16 could have 5-6 
citations apiece.  Therefore, the G-index 
allows for more highly cited articles to carry a 
larger weight than those with few citations.  
The disadvantage is there is still some 
debate over whether this is a more 
appropriate index to use compared to the H-
















A great overview of these citation indices 
can be found from Cornell University here. 
—Amy K. Starosciak, Ph.D., Director of 
Outcomes Research, Center for Research 
Amy’s Google Scholar Citation Indices as of 2/25/21 
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Explore our new publications! 
New Article Alcove 
Ahmad KA, Darcy-Mahoney A, et al. (2021) Longitudinal Survey of COVID-19 
Burden and Related Policies in U.S. Neonatal Intensive Care Units. Am J Perinatol 
38(1): 93-98.  Find it here! 
Askenazi DJ, Heagerty PJ, Schmicker RH...PENUT Consortium (includes Perez JE, 
Diaz-Barbosa M, Serize A, Jordan J, Bombino S) (in press) The Impact of 
Erythropoietin on Short and Long-term Kidney-Related Outcomes in Extremely 
Low Gestational Age Neonates. Results of a Multi-center Double-Blind Placebo-
Controlled Randomized Clinical Trial.  J Pediatr  Find it here! 
Bao R, Surriga O, Olson DJ..Bastos BR, et al. (2021) Transcriptional analysis of 
metastatic uveal melanoma survival nominates NRP1 as a therapeutic target .  
Melanoma Res 31(1): 27-37.  Find it here! 
*Chung DJ, *Arif B, Odia Y, Siomin V (2021) Chemotherapy-induced changes in tumor 
consistency can allow gross total resection of previously unresectable brainstem 
pilocytic astrocytoma. Surg Neurol Int 12:12.  Find it here! 
Conte E, Dwivedi A, Mushtaq S..Cury RC, et al. (2021) Age- and sex-related 
features of atherosclerosis from coronary computed tomography angiography in 
patients prior to acute coronary syndrome: results from the ICONIC 
study.  Eur Heart J Cardiovasc Imaging 22(1): 24-33.  Find it here! 
Czap AL, Zha AM, Sebaugh J...Linfante I, Starosciak AK, et al. (in press) 
Endovascular thrombectomy time metrics in the era of COVID-19: 
observations from the SVIN Multicenter Collaboration. J Neurointerv 
Surg Find it here!  
Davis 3rd WA & Yagnik GP (2021) In-Season Management of Acute 
and Subacute Sports Foot Injuries. Foot Ankle Clin 26(1): 187-203.  
Find it here! 
Kulik A, Abreu AM, Bonorat V, Ruel M (2020) Impact of lipid levels 
and high-intensity statins on vein graft patency after CABG: Midterm 
results of the ACTIVE trial. J Card Surg 35(12): 3286-3293.  Find it here! 
Leitao Jr MM, Zhou QC, Schiavone MB...Lambrou NC, Diaz 
JP, Zivanovic O (2021) Prophylactic Negative Pressure Wound Therapy 
After Laparotomy for Gynecologic Surgery: A Randomized Controlled 
Trial.  Obstet Gynecol 137(2): 334-341.  Find it here! 
Peña CS, Tuncay V, Benenati JF, Powell A, Gandhi RT, Schiro BJ, van 
Alfen M, Katzen BY (2021) Improving IR Ergonomics Using a Flexible C-
Arm System. J Vasc Interv Radiol 32(2): 220-225.  Find it here! 
Scaborough JA, Tom MC, Kattan MW, Scott JG (2021) Revisiting a null 
hypothesis: exploring the parameters of oligometastasis treatment. Int J 
Radiat Oncol Biol Phys S0360-3016(20): 34740-34744.  Find it here! 
van Lier MGJTB, de Groot JE, Muller S...Schilling KJ  (2020) Pressure-
based Compression Guidance of the Breast in Digital Breast 
Tomosynthesis Using Flexible Paddles Compared to Conventional 
Compression. J Breast Imag 2(6): 541-551.  Find it here! 
Photo by Henry Be on Unsplash 
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Tuesdays 12:00 to 1:00 pm 
Invite was sent out to Research Operations & 
Regulatory teams. Certificates provided. 
Because of the COVID-19 pandemic, we will be 
doing Zoom™ meetings only until further notice. 
Click here or go to baptisthealth.zoom.us  
Meeting ID: 958 8490 1869 
Password: 861787 
Date Topic 
Tuesday, March 9th Study Startup 
Tuesday, April 13th Audit Preparation 
Tuesday, May 11th Clinical Trial Agreement (CTA) Basics 
Tuesday, June 8th Research Finance Basics 
Tuesday, July 13th Appraisal of Statistical Methods in Research by Emir Veledar, Ph.D. 
Tuesday, August 10th Principles of Good Clinical Practice 
Tuesday, September 14th Participant Safety 
Tuesday, October 12th Preventing Noncompliance 
Tuesday, November 9th Participant Recruitment 
Tuesday, December 14th Study Documentation 
by Nursing & Clinical Research Organizations 
UPCOMING CONFERENCES 
Onsemble—April 19-22, 2021, Virtual 
https://conference.onsemble.net/ 
MAGI—April 26-May 6, 2021, Virtual 
https://www.magiworld.org/ 
 ACRP— May 14-17, 2021, Toronto, Canada 
https://acrpnet.org/event/acrp-2021-annual-conference/ 
SOCRA—September 24-26, 2021, Denver, CO 
https://www.socra.org/annual-conference/future-annual-conference-dates/  
Nursing World Conference—October 18-21, 2021, Virtual 
https://nursingworldconference.com/  
ANCC Magnet & Pathway—November 11-13, 2021, Atlanta, GA  
https://www.magnetcon.org/ 
Center for Research 
Invites you to attend 
Virtual Spring Onsemble 
April 19-22, 2021 
Sign up: https://conference.onsemble.net  
Free registration courtesy of Center for Research 




To serve as a 
research hub for 
elevating care 
through discovery for 
the diverse 
community we serve 
by using a shared 




collaborative intellect.  
 
VISION 
In alignment with the 
strategic goals of 
Baptist Health South 
Florida, and within the 
context of a 
sustainable business 




knowledge with the 
goals of providing 
continued excellence 
in patient care for the 
diverse multicultural 
community of South 
Florida. 
The Clinical Conflict of Interest (CCOI) form is a requirement for 
those who participate in research at BHSF that must be completed, 
at minimum, annually. Currently, all employees of BHSF are able to 
access, complete, and submit this form via PeopleSoft and all non-
employees are sent a PDF version via email. Research Compliance 
and Library & Research Support are collaborating to transition the 
PDF to an electronic form via REDCap. This transition will enable 
any non-employee (volunteer, student, external physician, etc.) to 
access the form via an email link. The CCOI e-form will increase 
efficiency and accessibility as it can be completed via computer, 
phone, tablet, etc. Research Compliance aims to have this e-form 
complete to use during the 2021 Annual Disclosure Period. As such, 
once it is live we recommend that study teams no longer use the 
PDF version of the CCOI form. 
All employed investigators must continue to complete the CCOI form 
via PeopleSoft. If you or a study team member are unable to access 
the form in PeopleSoft or are a non-employed researcher, please 
contact ResearchCompliance@baptisthealth.net. 
Do you have any questions or topics you would 
like for us to cover regarding conflicts of interest, 
compliance review, or billing compliance process? 
If so, contact us directly for all Research 
Compliance matters! 
Heather Osorio, Research Compliance & Billing 
Administrator, ResearchCompliance@baptisthealth.net   
Research Compliance Corner 
To contribute to this newsletter, please contact Dr. Amy Starosciak at amyst@baptisthealth.net or x79546. 
UPCOMING IRB DATES 
BHSF IRB 
Full Board Committee Meeting: Tuesday, March 23rd 
Submission Deadline for April Meeting: Monday, March 29th 
MCI IRB 
Full Board Committee Meeting: Monday,  April 5th 
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